Design, Synthesis, and Biological Evaluation of New 8-Trifluoromethylquinoline Containing Pyrazole-3-carboxamide Derivatives

dc.contributor.authorNayak, N.
dc.contributor.authorRamprasad, J.
dc.contributor.authorUdayakumar, U.
dc.date.accessioned2026-02-05T09:32:48Z
dc.date.issued2017
dc.description.abstractThe article describes the design, synthesis, and characterization of a new series of 8-trifluoromethylquinoline substituted pyrazole-3-carboxamides (9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 9j, 9k, 9l, 9m, 9n, 9o, 9p, 9q, 9r, 9s, 9t) derived from different primary and secondary amines. The intermediate and target compounds were characterized using spectroscopic methods. The structures of intermediate 7 and target molecule 9d were evidenced by the single crystal X-ray study. All the synthesized target compounds (9a, 9b, 9c, 9d, 9e, 9f, 9g, 9h, 9i, 9j, 9k, 9l, 9m, 9n, 9o, 9p, 9q, 9r, 9s, 9t) and three intermediates (6, 7, 8) were screened for their in vitro antitubercular activity against Mycobacterium tuberculosis H<inf>37</inf>Rv strain. Two compounds, 9k and 9t, showed significant inhibition activity with MIC of 3.13 µg/mL, which is comparable with the activity of standard drug, ethambutol. The carboxamides derived from benzylamine derivatives were more active than their aniline analogs. In general, the hybrid amides with a N-methylene linkage (-CONHCH<inf>2</inf>-) exhibited enhanced antitubercular activity. In the antibacterial screening, intermediate 3-hydrazinyl-2-methyl-8-(trifluoromethyl)quinoline (6) displayed remarkable activity against the tested bacterial strains. Further, the active anti-TB derivatives were non-toxic to benign NIH 3T3 cells, which demonstrate the lack of general cellular toxicity and hence signifies their suitability for further lead development. © 2015 HeteroCorporation
dc.identifier.citationJournal of Heterocyclic Chemistry, 2017, 54, 1, pp. 171-182
dc.identifier.issn0022152X
dc.identifier.urihttps://doi.org/10.1002/jhet.2564
dc.identifier.urihttps://idr.nitk.ac.in/handle/123456789/25839
dc.publisherHeteroCorporation
dc.subject(2,6 dimethylmorpholino)[1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl]methanone
dc.subject1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl) n [[4 (trifluoromethoxy)phenyl]methyl]pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl) n [[4 (trifluoromethyl)phenyl]methyl]pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] n (4 tolylmethyl) 5 (3 pyridyl)pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n (2,2,2 trifluoroethyl) 1h pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n 3 tolyl 1h pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n 4 tolyl 1h pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n [3 (trifluoromethyl)phenyl] 1h pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n [4 (trifluoromethoxy)phenyl] 1h pyrazole 3 carboxamide
dc.subject1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) n [4 (trifluoromethyl)phenyl] 1h pyrazole 3 carboxamide
dc.subjectamide
dc.subjectantibiotic agent
dc.subjectciprofloxacin
dc.subjectethambutol
dc.subjectisoniazid
dc.subjectn (4 fluorophenyl) 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide
dc.subjectn (4 methoxyphenyl) 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide
dc.subjectn (cyclopropylmethyl) 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide
dc.subjectn cyclopropyl 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide
dc.subjectn tert butyl 1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazole 3 carboxamide
dc.subjectn [(4 fluorophenyl)methyl] 1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl)pyrazole 3 carboxamide
dc.subjectn [(4 methoxyphenyl)methyl] 1 [2 methyl 8 (trifluoromethyl) 4 quinolyl] 5 (3 pyridyl)pyrazole 3 carboxamide
dc.subjectpyrazinamide
dc.subjectpyrazole derivative
dc.subjectquinoline derivative
dc.subjecttuberculostatic agent
dc.subjectunclassified drug
dc.subject[1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl](4 methyl piperidin 1 yl)methanone
dc.subject[1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl](morpholino)methanone
dc.subject[1 [2 methyl 8 (trifluoromethyl)quinolin 4 yl] 5 (pyridin 3 yl) 1h pyrazol 3 yl](piperidin 1 yl)methanone
dc.subject3T3 cell line
dc.subjectantibacterial activity
dc.subjectArticle
dc.subjectbacterial growth
dc.subjectbacterial strain
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectdrug cytotoxicity
dc.subjectdrug design
dc.subjectdrug screening
dc.subjectdrug structure
dc.subjectdrug synthesis
dc.subjectEscherichia coli
dc.subjectin vitro study
dc.subjectminimum inhibitory concentration
dc.subjectMycobacterium tuberculosis
dc.subjectnonhuman
dc.subjectPseudomonas aeruginosa
dc.subjectStaphylococcus aureus
dc.subjectX ray crystallography
dc.titleDesign, Synthesis, and Biological Evaluation of New 8-Trifluoromethylquinoline Containing Pyrazole-3-carboxamide Derivatives

Files

Collections